References
- Hill A, Richards S J, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol 2007; 137: 181–192
- Maciejewski J P, Sloand E M, Sato T, Anderson S, Young N S. Impaired hematopoiesis in paroxysmal nocturnal hemoglobinuria/aplastic anemia is not associated with a selective proliferative defect in the glycosylphosphatidylinositol-anchored protein-deficient clone. Blood 1997; 89: 1173–1181
- Young N S, Maciejewski J P. Genetic and environmental effects in paroxysmal nocturnal hemoglobinuria: this little PIG-A goes “Why? Why? Why?”. J Clin Invest 2000; 106: 637–641
- Rawstron A C, Rollinson S J, Richards S, Short M A, English A, Morgan G J, et al. The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment. Br J Haematol 1999; 107: 148–153
- Fracchiolla N S, Barcellini W, Bianchi P, Motta M, Fermo E, Cortelezzi A. Biological and molecular characterization of PNH-like lymphocytes emerging after Campath-1H therapy. Br J Haematol 2001; 112: 969–971
- Risitano A M, Kook H, Zeng W, Chen G, Young N S, Maciejewski J P. Oligoclonal and polyclonal CD4 and CD8 lymphocytes in aplastic anemia and paroxysmal nocturnal hemoglobinuria measured by V beta CDR3 spectratyping and flow cytometry. Blood 2002; 100: 178–183
- Barcellini W, Fermo E, Imperiali F G, Zaninoni A, Bianchi P, Boschetti C, et al. Increased resistance of PIG-A− bone marrow progenitors to tumor necrosis factor α and interferon γ: possible implications for the in vivo dominance of paroxysmal nocturnal hemoglobinuria clones. Haematologica 2004; 89: 651–656
- Raiola A M, Van Lint M T, Lamparelli T, Gualandi F, Benvenuto F, Figari O, et al. Bone marrow transplantation for paroxismal nocturnal hemoglobinuria. Haematologica 2000; 85: 59–62
- Takahashi Y, McCoy J P, Jr, Carvallo C, Rivera C, Igarashi T, Srinivasan R, et al. In vitro and in vivo evidence of PNH cell sensitivity to immune attack after nonmyeloablative allogeneic hematopoietic cell transplantation. Blood 2004; 103: 1383–1390
- Boschetti C, Fermo E, Bianchi P, Vercellati C, Barraco F, Zanella A. Clinical and molecular aspects of 23 patients affected by paroxysmal nocturnal hemoglobinuria. Am J Hematol 2004; 77: 36–44
- Sambrook J, Fritsch E F, Maniatis T. Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1989
- Iida Y, Takeda J, Miyata T, Inoue N, Nishimura J, Kitani T, et al. Characterization of genomic PIG-A gene. A gene for glycosylphosphatidylinositol-anchor biosynthesis and paroxysmal nocturnal hemoglobinuria. Blood 1994; 83: 3126–3131
- Coluzzi S, Biffoni M, Pasqualetti D, et al. Production of interferon-γ by lymphocytes from paroxysmal nocturnal haemoglobinuria patients: relationship with clinical status. Br J Haematol 2004; 124: 685–690
- Poggi A, Negrini S, Zocchi M R, et al. Patients with paroxysmal nocturnal hemoglobinuria have a high frequency of peripheral-blood T cells expressing activating isoforms of inhibiting superfamily receptors. Blood 2005; 106: 2399–2408
- Fermo E, Bianchi P, Barcellini W, Pedotti P, Boschetti C, Alfinito F, et al. Immunoregulatory cytokine polymorphisms in Italian patients affected by paroxysmal nocturnal hemoglobinuria and aplastic anemia. Eur J Immunogen 2004; 31: 267–269
- Nishimura J, Ware R E, Burnette A, et al. The hematopoietic defect in PNH is not due to defective stroma, but is due to defective progenitors cells. Blood Cells Mol Dis 2002; 29: 159–167